Y-mAbs Therapeutics, Inc., has completed submission of a Biologics License Application (BLA) to the FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.1
Commenting on the BLA submission, Claus Moller, MD, PhD, chief executive officer of Y-mAbs, said in the press release, “With this submission, we look forward to working with the [FDA] to bring naxitamab to appropriate patients. We are excited to complete this submission and believe naxitamab can address a significant unmet medical need for children with relapsed/refractory high-risk neuroblastoma.”
- Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA. Published April 1, 2020. https://bit.ly/2R74fLy. Accessed April 4, 2020.
- Y-mAbs Announces Naxitamab Update. Published October 25, 2019. https://bit.ly/2V3exNU. Accessed April 4, 2020.
- Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma. Published August 21, 2018. https://bit.ly/2UWURv8. Accessed April 4, 2020.
... to read the full story